Proprietary Cytotoxic Payloads Technology

Proprietary Cytotoxic Payloads


Eribulin Mesylate


  • Eribulin*
  • Next-generation cytotoxins


Single-Dose in vivo Efficacy


Eribulin Drug Conjugate*:

  • Eribulin (Halaven®), the payload
  • In preclinical studies, the ADC format exhibited:
    • Potent antitumor activity
    • Good safety profile

* Any antibody drug conjugate (ADC) employing eribulin as a payload is investigational and has not been approved by regulatory authorities. For information on Halaven® (eribulin mesylate), please see the package insert or contact Eisai’s Medical Information toll-free number 1.888.274.2378.